
Cytokeratin 19 Antibody A53-B/A2.26 / CK19 Monoclonal Antibody [clone A53-B/A2.26] (V2179)

Catalog No.	Formulation	Size
V2179-100UG	0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide	100 ug
V2179-20UG	0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide	20 ug
V2179SAF-100UG	1 mg/ml in 1X PBS; BSA free, sodium azide free	100 ug
V2179IHC-7ML	Prediluted in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide; *For IHC use only*	7 ml


Citations (7)

Bulk quote request


Species Reactivity	Human
Format	Purified
Host	Mouse
Clonality	Monoclonal (mouse origin)
Isotype	Mouse IgG2a, lambda
Clone Name	A53-B/A2.26
Purity	Protein G affinity chromatography
Buffer	1X PBS, pH 7.4
Gene ID	3880
Localization	Cytoplasmic
Applications	Western blot: 1-2ug/ml Immunofluorescence: 1-2ug/ml Immunohistochemistry (FFPE): 1-2ug/ml for 30 min at RT
Limitations	This Cytokeratin 19 Antibody A53-B/A2.26 / CK19 Monoclonal Antibody is available for research use only.




Cytokeratin 19 Antibody A53-B/A2.26 by WB in human HepG2 and MCF7 cells. Western blot analysis of human HepG2 (lane 1) and MCF7 (lane 2) cell lysates using Cytokeratin 19 Antibody clone A53-B/A2.26. Both lanes exhibit prominent immunoreactive bands migrating near the 44 kDa molecular weight marker, consistent with the predicted molecular weight of KRT19 of approximately 43 kDa. The bands are sharply defined, with comparable migration positions and relatively little background staining. No prominent additional bands are visible within the displayed molecular weight range. The CK19 Monoclonal Antibody demonstrates recognition of a protein migrating near the expected size of cytokeratin 19 in two human epithelial carcinoma cell models.




Cytokeratin 19 Antibody A53-B/A2.26 by WB in human PC3 cells. Western blot analysis of human PC3 prostate carcinoma cell lysate using Cytokeratin 19 Antibody clone A53-B/A2.26. A prominent immunoreactive band is detected at approximately 45 kDa, migrating between the 37 and 50 kDa molecular weight markers and closer to the latter. This position is consistent with the expected molecular weight of human cytokeratin 19, approximately 43 kDa. The band is relatively broad but well defined, with no prominent additional immunoreactive bands visible within the displayed molecular weight range. The CK19 Monoclonal Antibody demonstrates recognition of a protein migrating near the expected molecular weight of KRT19 in human PC3 cells.



Cytokeratin 19 Antibody A53-B/A2.26 by IHC in human colon carcinoma. Immunohistochemistry of formalin-fixed, paraffin-embedded human colon carcinoma tissue using Cytokeratin 19 Antibody clone A53-B/A2.26. Strong brown cytoplasmic immunoreactivity highlights irregularly shaped glandular epithelial structures surrounding distinct luminal spaces. The staining is concentrated within the carcinoma cells, with prominent labeling throughout the cytoplasm and along the contours of the glandular formations. Numerous unstained nuclei are visible within the positively stained epithelial structures, while the intervening stromal tissue exhibits comparatively limited immunoreactivity. Hematoxylin counterstaining reveals nuclei in blue. The CK19 Monoclonal Antibody demonstrates KRT19 expression within the gland-forming epithelial components of human colon carcinoma. Heat-induced epitope retrieval was performed using 10 mM citrate buffer, pH 6, for 10-20 minutes, followed by cooling at room temperature for 20 minutes.



Cytokeratin 19 Antibody A53-B/A2.26 by IF in human MCF7 cells. Immunofluorescence staining of methanol-fixed human MCF7 breast carcinoma cells using Cytokeratin 19 Antibody clone A53-B/A2.26, detected in cyan-blue fluorescence, with RedDot nuclear counterstaining in red. Strong cytoplasmic fluorescence highlights an extensive filamentous network surrounding the nuclei and extending throughout the cell bodies. The staining is particularly prominent within the perinuclear cytoplasm and along the interconnected filamentous structures of adjacent cells. Individual nuclei appear dark red against the surrounding cytoplasmic fluorescence. The CK19 Monoclonal Antibody demonstrates the characteristic intermediate filament-associated distribution of KRT19 in human epithelial carcinoma cells.



SDS-PAGE analysis of purified, BSA-free Cytokeratin 19 antibody (clone A53-B/A2.26) as confirmation of integrity and purity.

Description

Cytokeratin 19 Antibody A53-B/A2.26 / CK19 Monoclonal Antibody recognizes keratin 19, a type I intermediate filament protein encoded by the KRT19 gene. Clone A53-B/A2.26 recognizes an epitope within amino acids 312-335 of human KRT19, located in its alpha-helical rod domain. This mapped epitope distinguishes the clone from other cytokeratin 19 antibodies and provides a molecular reference for comparing antibody recognition across experimental studies. KRT19 is structurally unusual among type I keratins because it lacks the extended C-terminal tail domain characteristic of many family members.

KRT19 contributes to epithelial cytoskeletal organization by associating with compatible type II keratins, particularly keratin 8, to form intermediate filament networks. These structures help epithelial cells maintain their architecture and withstand mechanical stress. KRT19 is expressed in numerous simple, glandular, and ductal epithelia, including mammary ducts, pancreatic ducts, biliary epithelial cells, and gastrointestinal tissues. The CK19 Monoclonal Antibody is therefore relevant to investigations of epithelial differentiation, cellular organization, and tissue remodeling.

In cancer research, KRT19 is widely studied as a marker of epithelial lineage and differentiation. Its expression is frequently retained in carcinomas arising from the breast, pancreas, lung, thyroid, and gastrointestinal tract. Immunohistochemical detection of KRT19 can help characterize epithelial tumor populations and their distribution within surrounding tissue. However, KRT19 expression is not specific to malignancy, and its interpretation requires consideration of tissue morphology and complementary molecular markers.

Clone A53-B/A2.26 has an established history in cytokeratin research, with 103 publications reported by Bioz. This substantial literature presence makes its clone identity particularly valuable for researchers seeking continuity with previously published experimental methods and findings. Its defined epitope within the KRT19 rod domain provides an additional consideration when comparing antibody performance, although epitope mapping alone does not establish specificity against related keratins. The Cytokeratin 19 Antibody A53-B/A2.26 is consequently of interest for studies requiring a well-documented monoclonal clone.

NSJ Bioreagents provides this mouse monoclonal antibody for investigating KRT19 expression in human epithelial tissues and carcinoma models. Its established research history and defined epitope support studies of epithelial differentiation, intermediate filament organization, and carcinoma-associated keratin expression.

For additional KRT19 detection options, see our anchor Cytokeratin 19 Antibody KRT19/799 | CK19 | V2678.

Application Notes

The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the Cytokeratin 19 Antibody A53-B/A2.26 / CK19 Monoclonal Antibody to be titered up or down for optimal performance.

1. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM Citrate Buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes.
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

Immunogen

Human breast cancer MCF-7 cells were used as the immunogen for this Cytokeratin 19 antibody.

Storage

Store the Cytokeratin 19 antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).

Alternate Names

KRT19 antibody, CK19 antibody, Keratin 19 antibody, K19 antibody, Type I Cytoskeletal Keratin 19 antibody, Cytokeratin-19 antibody

References (1)

Copyright © NSJ Bioreagents. All rights reserved.